Diabetes Mellitus, Diabetic Neuropathies, Herpes Zoster, HIV Infections, Neuralgia, Pain, Peripheral Nervous System Diseases, Polyneuropathies
Conditions
Keywords
Dermal assessment, Pain assessment, Diary, Analgesics, Capsaicin, Herpes zoster, Neuralgia, Pain, HIV Infections, Peripheral Nervous System Diseases, Diabetic Neuropathies, Diabetes Mellitus, Polyneuropathies, Complementary Therapies
Brief summary
This study is an open-label, multicenter, extension study for subjects who completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7days) before entry into Study C114
Interventions
Sponsors
NeurogesX
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Eligibility Criteria: * Must have completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7 days) before entry into Study C114. * Demonstrated adherence to protocol requirements during Study C111, and willing and able to comply with protocol requirements for the duration of the study participation. * Must not have had any serious adverse experience since enrollment in Study C111, whether or not considered to be study drug-related. * Must have intact skin at the treatment area. * Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (36 weeks). * Must not use topical pain medications on painful areas. * Must be at least 18 years old, not pregnant, and able to take care of self independently, with only occasional assistance if needed. * No history or current problem with substance abuse.
Outcome results
None listed